PeppiLibrary

Growth Hormone

Sermorelin peptide reference

GHRH analog. Stimulates the pituitary to release endogenous growth hormone.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Sermorelin notes
Default dose label200 mcg
Preferred routeSubQ
Frequency label1× nightly (typical) or 2× daily
Storage window30 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved (paediatric, 1990 — discontinued for commercial reasons)

Prescription medication; available via compounding pharmacies

Route map

How records are usually labeled

1 SubQ
2 IM

Rotate around the abdomen to minimise lipoatrophy.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze for long-term.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 3 mg vial
Dose 200 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Sermorelin. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Sermorelin is a 29-amino-acid analog corresponding to the active fragment of growth hormone-releasing hormone (GHRH). Rather than supplying exogenous GH, it signals the pituitary to release the body's own GH in a pulsatile, more physiological pattern. It was FDA-approved in 1990 for paediatric GH deficiency (later withdrawn for commercial reasons, not safety).

Also known as: GHRH(1-29), GRF 1-29, Geref.

Adult GH deficiency supportSleep qualityRecovery and lean-mass supportAnti-aging research

Mechanism and timing snapshot

Binds the GHRH receptor on pituitary somatotrophs, triggering cAMP-mediated GH synthesis and release. Effects are pulsatile and self-limiting via somatostatin negative feedback.

Onset label15 min
Catalog onset field, when available.
Half-life label12 min
~10–20 minutes in plasma; biological GH pulse lasts longer
Duration label2 hr
Catalog duration field, when available.
subQ High
oral Negligible (peptide degraded by gastric enzymes)

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose200 mcg
Catalog dose range100 mcg - 500 mcg
Default routeSubQ
Frequency label1× nightly (typical) or 2× daily
Best time labelPre-bed (aligns with natural nocturnal GH pulse).
Food noteTake on an empty stomach — high blood sugar or fat intake within 2 hours blunts the GH pulse.

Catalog protocol note

100–300 mcg subQ once nightly on an empty stomach, 5 nights on / 2 off, for 3–6 months.

Routes and site notes

Available route labelsSubQ, IM
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate around the abdomen to minimise lipoatrophy.

Chemistry

SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSR
Amino acids29
Molecular formulaC149H246N44O42S
Molecular weight3358 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size3 mg
DiluentBacteriostatic water
Diluent volume3 mL
Concentration note3 mg in 3 mL → 0.10 mL = 100 mcg (10 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze for long-term.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Injection-site flushing or tingling
  • Mild headache
  • Vivid dreams
  • Transient water retention
  • Mild glucose intolerance

Contraindications and warnings

  • Active malignancy
  • Severe respiratory impairment
  • Pregnancy
  • Not a substitute for medically prescribed HGH in deficiency.

Other considerations

  • Effects build over weeks; visible changes typically take 2–3 months.
  • Empty-stomach dosing matters — high insulin blunts the pulse.

Evidence and regulatory context

Evidence levelFDA-approved (paediatric, 1990 — discontinued for commercial reasons)
FDA approvedYes
Regulatory statusPrescription medication; available via compounding pharmacies
Prescription requiredYes
Approved countriesUS

Stacking and cycle notes

Stacks well withipamorelin, cjc-1295
Avoid combining noteOther GHRH analogs simultaneously
Typical cycle label12–24
Typical break label4–8
Cycle guidanceLong cycles (3–6 months) are typical because effects accumulate. Periodic breaks help receptor sensitivity.

Tracking tips

  • Dose pre-bed on an empty stomach for the strongest natural GH pulse.
  • Pairs with Ipamorelin for combined GHRH + secretagogue effect.
  • Be patient — visible body composition changes take 8–12 weeks.

References

Track it in Peppi

Keep Sermorelin records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Sermorelin?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Sermorelin?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Sermorelin records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026